Drug intelligence / Profile preview

KH110

Development stage: Unknown
Lead developer: Chengdu Kanghong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KH110 is an innovative proprietary Chinese patent medicine developed for the treatment of Alzheimer's disease. It is also known as Wujia Yizhi granule and is currently in Phase II clinical trials in China. The drug has shown promising preclinical efficacy, but its precise mechanism of action has not been disclosed publicly. It represents a novel approach to Alzheimer's therapy from Kanghong Pharmaceutical, aiming to address the unmet need for effective treatments for this progressive neurodegenerative disorder[1][2].

Brand names: Wujia Yizhi granule
Other names: Wujia Yizhi granuleKH110KH-110KH 110

Beyond the preview

Go deeper on KH110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KH110.

Explore the full profile